Alamar Biosciences Launches NULISAseq™ Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease researchNew panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 12 assays specific to brain and peripheral Tau isoforms | NULISA™ data to be presented in over 11 scientific sessions and 25 posters at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2026)
